Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant

Jeffrey J. Gaynor, Gaetano Ciancio, Giselle Guerra, Junichiro Sageshima, Lois Hanson, David Roth, Michael J. Goldstein, Linda Chen, Warren Kupin, Adela Mattiazzi, Lissett Tueros, Sandra Flores, Luis J. Barba, Adrian Lopez, Jose Rivas, Phillip Ruiz, Rodrigo Vianna, George W. Burke

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Aims/hypothesis: To better understand the implications of new-onset diabetes after transplant (NODAT), we used our prospectively followed cohort of 628 adult primary kidney transplant recipients to determine the prognostic impact of pretransplant diabetes and NODAT.

Methods: The study cohort consisted of all participants in four randomised immunosuppression trials performed at our centre since May 2000. For each cause-specific hazard analysed, Cox stepwise regression was used to determine a multivariable model of significant baseline predictors; the multivariable influence of having pretransplant diabetes and NODAT (t) (the latter defined as a zero-one, time-dependent covariate) was subsequently tested. Similar analyses of estimated glomerular filtration rate (eGFR) at 36 and 60 months post transplant were performed using stepwise linear regression. Finally, a repeated measures analysis of mean HbA1c as a function of diabetes category (pretransplant diabetes vs NODAT) and randomised trial (first to fourth) was performed.

Results: Median follow-up was 56 months post transplant. Patients with pretransplant diabetes comprised 23.4% (147/628), and 22.5% (108/481) of the remaining patients developed NODAT. Pretransplant diabetes had no prognostic influence on first biopsy-proven acute rejection and death-censored graft failure hazard rates, nor on eGFR, but was associated with significantly higher rates of death with a functioning graft (DWFG) (p = 0.003), DWFG due to a cardiovascular event (p = 0.005) and infection that required hospitalisation (p = 0.03). NODAT (t) had no unfavourable impact on any of these hazard rates nor on eGFR, with actuarial freedom from DWFG remaining at over 90% among patients in pre- and post-NODAT states at 72 months post transplant/NODAT. Mean HbA1c for patients in the first to fourth randomised trials, averaged across diabetes category, decreased by trial (7.28%, 6.92%, 6.87% and 6.64% [56.1, 52.1, 51.6 and 49.1 mmol/mol], respectively; p = 0.02).

Conclusions/interpretation: Less-than-expected post-NODAT risk for graft loss and death may exist in the current climate of tighter glucose monitoring post transplant.

Original languageEnglish (US)
Pages (from-to)334-345
Number of pages12
JournalDiabetologia
Volume58
Issue number2
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Transplants
Kidney
Glomerular Filtration Rate
Transplant Recipients
Climate
Immunosuppression
Linear Models
Hospitalization
Cohort Studies
Biopsy
Glucose

Keywords

  • Kidney transplantation
  • New-onset diabetes after transplant
  • Pretransplant diabetes mellitus
  • Prognostic impact

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant. / Gaynor, Jeffrey J.; Ciancio, Gaetano; Guerra, Giselle; Sageshima, Junichiro; Hanson, Lois; Roth, David; Goldstein, Michael J.; Chen, Linda; Kupin, Warren; Mattiazzi, Adela; Tueros, Lissett; Flores, Sandra; Barba, Luis J.; Lopez, Adrian; Rivas, Jose; Ruiz, Phillip; Vianna, Rodrigo; Burke, George W.

In: Diabetologia, Vol. 58, No. 2, 01.01.2014, p. 334-345.

Research output: Contribution to journalArticle

Gaynor, JJ, Ciancio, G, Guerra, G, Sageshima, J, Hanson, L, Roth, D, Goldstein, MJ, Chen, L, Kupin, W, Mattiazzi, A, Tueros, L, Flores, S, Barba, LJ, Lopez, A, Rivas, J, Ruiz, P, Vianna, R & Burke, GW 2014, 'Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant', Diabetologia, vol. 58, no. 2, pp. 334-345. https://doi.org/10.1007/s00125-014-3428-0
Gaynor, Jeffrey J. ; Ciancio, Gaetano ; Guerra, Giselle ; Sageshima, Junichiro ; Hanson, Lois ; Roth, David ; Goldstein, Michael J. ; Chen, Linda ; Kupin, Warren ; Mattiazzi, Adela ; Tueros, Lissett ; Flores, Sandra ; Barba, Luis J. ; Lopez, Adrian ; Rivas, Jose ; Ruiz, Phillip ; Vianna, Rodrigo ; Burke, George W. / Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant. In: Diabetologia. 2014 ; Vol. 58, No. 2. pp. 334-345.
@article{dd77f5d032b4444ba77e0a11848d3ead,
title = "Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant",
abstract = "Aims/hypothesis: To better understand the implications of new-onset diabetes after transplant (NODAT), we used our prospectively followed cohort of 628 adult primary kidney transplant recipients to determine the prognostic impact of pretransplant diabetes and NODAT.Methods: The study cohort consisted of all participants in four randomised immunosuppression trials performed at our centre since May 2000. For each cause-specific hazard analysed, Cox stepwise regression was used to determine a multivariable model of significant baseline predictors; the multivariable influence of having pretransplant diabetes and NODAT (t) (the latter defined as a zero-one, time-dependent covariate) was subsequently tested. Similar analyses of estimated glomerular filtration rate (eGFR) at 36 and 60 months post transplant were performed using stepwise linear regression. Finally, a repeated measures analysis of mean HbA1c as a function of diabetes category (pretransplant diabetes vs NODAT) and randomised trial (first to fourth) was performed.Results: Median follow-up was 56 months post transplant. Patients with pretransplant diabetes comprised 23.4{\%} (147/628), and 22.5{\%} (108/481) of the remaining patients developed NODAT. Pretransplant diabetes had no prognostic influence on first biopsy-proven acute rejection and death-censored graft failure hazard rates, nor on eGFR, but was associated with significantly higher rates of death with a functioning graft (DWFG) (p = 0.003), DWFG due to a cardiovascular event (p = 0.005) and infection that required hospitalisation (p = 0.03). NODAT (t) had no unfavourable impact on any of these hazard rates nor on eGFR, with actuarial freedom from DWFG remaining at over 90{\%} among patients in pre- and post-NODAT states at 72 months post transplant/NODAT. Mean HbA1c for patients in the first to fourth randomised trials, averaged across diabetes category, decreased by trial (7.28{\%}, 6.92{\%}, 6.87{\%} and 6.64{\%} [56.1, 52.1, 51.6 and 49.1 mmol/mol], respectively; p = 0.02).Conclusions/interpretation: Less-than-expected post-NODAT risk for graft loss and death may exist in the current climate of tighter glucose monitoring post transplant.",
keywords = "Kidney transplantation, New-onset diabetes after transplant, Pretransplant diabetes mellitus, Prognostic impact",
author = "Gaynor, {Jeffrey J.} and Gaetano Ciancio and Giselle Guerra and Junichiro Sageshima and Lois Hanson and David Roth and Goldstein, {Michael J.} and Linda Chen and Warren Kupin and Adela Mattiazzi and Lissett Tueros and Sandra Flores and Barba, {Luis J.} and Adrian Lopez and Jose Rivas and Phillip Ruiz and Rodrigo Vianna and Burke, {George W.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00125-014-3428-0",
language = "English (US)",
volume = "58",
pages = "334--345",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant

AU - Gaynor, Jeffrey J.

AU - Ciancio, Gaetano

AU - Guerra, Giselle

AU - Sageshima, Junichiro

AU - Hanson, Lois

AU - Roth, David

AU - Goldstein, Michael J.

AU - Chen, Linda

AU - Kupin, Warren

AU - Mattiazzi, Adela

AU - Tueros, Lissett

AU - Flores, Sandra

AU - Barba, Luis J.

AU - Lopez, Adrian

AU - Rivas, Jose

AU - Ruiz, Phillip

AU - Vianna, Rodrigo

AU - Burke, George W.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aims/hypothesis: To better understand the implications of new-onset diabetes after transplant (NODAT), we used our prospectively followed cohort of 628 adult primary kidney transplant recipients to determine the prognostic impact of pretransplant diabetes and NODAT.Methods: The study cohort consisted of all participants in four randomised immunosuppression trials performed at our centre since May 2000. For each cause-specific hazard analysed, Cox stepwise regression was used to determine a multivariable model of significant baseline predictors; the multivariable influence of having pretransplant diabetes and NODAT (t) (the latter defined as a zero-one, time-dependent covariate) was subsequently tested. Similar analyses of estimated glomerular filtration rate (eGFR) at 36 and 60 months post transplant were performed using stepwise linear regression. Finally, a repeated measures analysis of mean HbA1c as a function of diabetes category (pretransplant diabetes vs NODAT) and randomised trial (first to fourth) was performed.Results: Median follow-up was 56 months post transplant. Patients with pretransplant diabetes comprised 23.4% (147/628), and 22.5% (108/481) of the remaining patients developed NODAT. Pretransplant diabetes had no prognostic influence on first biopsy-proven acute rejection and death-censored graft failure hazard rates, nor on eGFR, but was associated with significantly higher rates of death with a functioning graft (DWFG) (p = 0.003), DWFG due to a cardiovascular event (p = 0.005) and infection that required hospitalisation (p = 0.03). NODAT (t) had no unfavourable impact on any of these hazard rates nor on eGFR, with actuarial freedom from DWFG remaining at over 90% among patients in pre- and post-NODAT states at 72 months post transplant/NODAT. Mean HbA1c for patients in the first to fourth randomised trials, averaged across diabetes category, decreased by trial (7.28%, 6.92%, 6.87% and 6.64% [56.1, 52.1, 51.6 and 49.1 mmol/mol], respectively; p = 0.02).Conclusions/interpretation: Less-than-expected post-NODAT risk for graft loss and death may exist in the current climate of tighter glucose monitoring post transplant.

AB - Aims/hypothesis: To better understand the implications of new-onset diabetes after transplant (NODAT), we used our prospectively followed cohort of 628 adult primary kidney transplant recipients to determine the prognostic impact of pretransplant diabetes and NODAT.Methods: The study cohort consisted of all participants in four randomised immunosuppression trials performed at our centre since May 2000. For each cause-specific hazard analysed, Cox stepwise regression was used to determine a multivariable model of significant baseline predictors; the multivariable influence of having pretransplant diabetes and NODAT (t) (the latter defined as a zero-one, time-dependent covariate) was subsequently tested. Similar analyses of estimated glomerular filtration rate (eGFR) at 36 and 60 months post transplant were performed using stepwise linear regression. Finally, a repeated measures analysis of mean HbA1c as a function of diabetes category (pretransplant diabetes vs NODAT) and randomised trial (first to fourth) was performed.Results: Median follow-up was 56 months post transplant. Patients with pretransplant diabetes comprised 23.4% (147/628), and 22.5% (108/481) of the remaining patients developed NODAT. Pretransplant diabetes had no prognostic influence on first biopsy-proven acute rejection and death-censored graft failure hazard rates, nor on eGFR, but was associated with significantly higher rates of death with a functioning graft (DWFG) (p = 0.003), DWFG due to a cardiovascular event (p = 0.005) and infection that required hospitalisation (p = 0.03). NODAT (t) had no unfavourable impact on any of these hazard rates nor on eGFR, with actuarial freedom from DWFG remaining at over 90% among patients in pre- and post-NODAT states at 72 months post transplant/NODAT. Mean HbA1c for patients in the first to fourth randomised trials, averaged across diabetes category, decreased by trial (7.28%, 6.92%, 6.87% and 6.64% [56.1, 52.1, 51.6 and 49.1 mmol/mol], respectively; p = 0.02).Conclusions/interpretation: Less-than-expected post-NODAT risk for graft loss and death may exist in the current climate of tighter glucose monitoring post transplant.

KW - Kidney transplantation

KW - New-onset diabetes after transplant

KW - Pretransplant diabetes mellitus

KW - Prognostic impact

UR - http://www.scopus.com/inward/record.url?scp=84922004007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922004007&partnerID=8YFLogxK

U2 - 10.1007/s00125-014-3428-0

DO - 10.1007/s00125-014-3428-0

M3 - Article

C2 - 25361829

AN - SCOPUS:84922004007

VL - 58

SP - 334

EP - 345

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 2

ER -